论文信息 - Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia - 字舞流文

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

B. Smith | P. Sabbatini | J. Altman | J. Castro | L. Cohen | A. Yacoub | P. Becker | J. Foran | C. Dilea | M. Wade | A. Gutierrez | G. Xing